Virginia Retirement Systems ET AL increased its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS – Get Rating) by 20.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 43,000 shares of the company’s stock after acquiring an additional 7,200 shares during the quarter. Virginia Retirement Systems ET AL owned about 0.06% of Gossamer Bio worth $373,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Woodline Partners LP acquired a new position in shares of Gossamer Bio during the 4th quarter worth approximately $11,059,000. Smith Moore & CO. grew its holdings in Gossamer Bio by 95.0% in the 4th quarter. Smith Moore & CO. now owns 19,500 shares of the company’s stock valued at $221,000 after buying an additional 9,500 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Gossamer Bio by 347.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 30,210 shares of the company’s stock valued at $290,000 after buying an additional 23,460 shares in the last quarter. Emerald Mutual Fund Advisers Trust grew its holdings in Gossamer Bio by 14.4% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 1,805,305 shares of the company’s stock valued at $20,418,000 after buying an additional 227,558 shares in the last quarter. Finally, Emerald Advisers LLC grew its holdings in Gossamer Bio by 16.8% in the 4th quarter. Emerald Advisers LLC now owns 1,770,919 shares of the company’s stock valued at $20,029,000 after buying an additional 254,916 shares in the last quarter. 76.90% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:GOSS opened at $7.71 on Monday. The stock has a fifty day moving average price of $7.40 and a 200-day moving average price of $8.79. The company has a market cap of $594.57 million, a price-to-earnings ratio of -2.49 and a beta of 0.85. The company has a debt-to-equity ratio of 7.44, a quick ratio of 8.12 and a current ratio of 8.12. Gossamer Bio, Inc. has a fifty-two week low of $5.64 and a fifty-two week high of $14.30.
Gossamer Bio (NASDAQ:GOSS – Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.01. Research analysts predict that Gossamer Bio, Inc. will post -2.73 EPS for the current fiscal year.
In related news, insider Laura Carter sold 8,808 shares of the company’s stock in a transaction on Friday, July 1st. The stock was sold at an average price of $8.25, for a total transaction of $72,666.00. Following the completion of the sale, the insider now directly owns 80,234 shares in the company, valued at approximately $661,930.50. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders have sold 11,848 shares of company stock valued at $93,985. 8.30% of the stock is owned by corporate insiders.
A number of research analysts have commented on GOSS shares. UBS Group started coverage on Gossamer Bio in a report on Wednesday, April 6th. They issued a “buy” rating and a $19.00 price objective on the stock. Barclays decreased their price objective on Gossamer Bio from $18.00 to $12.00 and set an “overweight” rating on the stock in a report on Tuesday, April 26th. Piper Sandler decreased their price objective on Gossamer Bio from $26.00 to $15.00 in a report on Monday, April 25th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Gossamer Bio in a report on Monday, May 9th. Finally, Raymond James cut their target price on Gossamer Bio from $19.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, April 26th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $17.50.
About Gossamer Bio (Get Rating)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.
Featured Articles
Receive News & Ratings for Gossamer Bio Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gossamer Bio and related companies with MarketBeat.com’s FREE daily email newsletter.
George is Digismak’s reported cum editor with 13 years of experience in Journalism